Additionally, it was proposed that palbociclib, an inhibitor of cyclin dependent kinase 6 (CDK6), could serve as an alternative therapeutic choice for targeting cancers with SRSF2 mutations [114]. This evidence concerns the gene CDK6 and cancer.